Family Lifestyles, Actions, and Risk Education Intervention: Version 2
| 対象疾患 | Melanoma, Child |
|---|---|
| 相 | 該当なし |
| スポンサー | University of Utah |
| ステータス | 完了 |
| 参加者数 | 752 名 |
| 介入(薬剤) | FLARE Intervention |
| 開始日 | 2020年4月7日 |
| 完了日 | 2025年1月28日 |
| 結果公開日 | 2026年6月18日 |
概要
The overall purpose of this study is to determine the efficacy of the Family Lifestyles, Actions, and Risk Education (FLARE) intervention in improving melanoma preventive behaviors. Parent-child dyads, consisting of survivors of melanoma and their children, will be randomly assigned to either receive the FLARE intervention or standard education. Once enrolled, each parent-child dyad will participate in this study for just over 1 year. Both conditions will receive three bi-weekly live intervention sessions (30 minutes per session) with an interventionist, and quarterly boosters via text or email.
Parent Report on Child Sunburn Occurrence Assessed Via Sun Habits Survey
| FLARE Intervention | 0.59 ± .851 score on a scale |
|---|---|
| Standard Education | 0.63 ± 0.932 score on a scale |
| FLARE Intervention | 0.42 ± 0.611 score on a scale |
| Standard Education | 0.56 ± 0.837 score on a scale |
| FLARE Intervention | 0.29 ± 0.522 score on a scale |
| Standard Education | 0.51 ± 0.849 score on a scale |
BENITIONS で見る ClinicalTrials.gov の原文を見る
同じ疾患の他の治験
- A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration — National Cancer Institute (NCI)
- Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-I — National Cancer Institute (NCI)
- Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab — National Cancer Institute (NCI)
- Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With — Bristol-Myers Squibb
- Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Select — National Cancer Institute (NCI)
- Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, — National Cancer Institute (NCI)